Functional MRI Use in Prostate Radiation Treatment Planning

Abramson Cancer Center at Penn Medicine

Status

Completed

Conditions

Prostate Cancer

Treatments

Device: MRI

Study type

Interventional

Funder types

Other

Identifiers

NCT01985932

UPCC 07812

Details and patient eligibility

About

This study is being done to evaluate the use of MRI during radiation treatment planning to identify areas of tumor within the prostate to aid in future treatment planning and targeting of prostate cancer. This study will be conducted at the University of Pennsylvania Health System. The study is projected to run for 18 months. Subjects will be male 18 or older with a prostate cancer diagnosis and treatment plansat the Department of Radiation Oncology.

Enrollment

15 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 or older
Male
Biopsy proven prostate cancer without evidence of metastatic disease
Planned definitive external beam RT with daily ERB and implanted Visicoil fiducial markers.
Prior fMRI-ec documenting an IPL 25 mm2 in axial bidimensional diameter product, concordant with intraprostatic tumor location as documented on transrectal ultrasoundbiopsy
Subject capable of giving informed consent for standard external beam RT and for the study.
No current contraindication that would prevent MRI or gadolinium contrast.

Exclusion criteria

Metastatic disease
Lack of fMRI-ec documeneting an IPL 25 mm2 in axial bidimensional product, concordant with intraprostatic tumor location as documented on transrectal untrasound biopsy
Neoadjuvant androgen deprivation therapy greater than 10 weeks, defined from date of LHRH analog injection to date of fMRI-sim
Contraindication that would prevent MRI or gadolinium contrast
GFR 30 mL/min/1.73m2 per Crockoft-Gault formula.